CIENCIASMEDICASNEWS

jueves, 2 de julio de 2026

Why animal models still matter in drug development Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/why-animal-models-still-matter-in-drug-development-17275 Governments around the world are moving to reduce the use of animal models in preclinical research, driven by ethical concerns and rapid advances in new approach methodologies (NAMs). In the US, this transition has been accelerated by recent legislative changes. The FDA Modernization Act 2.0, enacted in 2022, removed the decades-old statutory requirement that animal testing be included in Investigational New Drug applications. Three years later, FDA Modernization Act 3.0 went further, directing the FDA to establish a formal process for qualifying nonclinical testing methods.

Reengineering cancer vaccines for durable immune memory Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/reengineering-cancer-vaccines-for-durable-immune-memory-17293?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_w6QR66mPoj9xCFxCKflFWaGdfRHmWRG_Ievh3ZnNTiVHMxpnSvjWRmgW9TEN0ZBwRL6DIyuhz4ldcKfXjaQBn_DB72g&_hsmi=426335944&utm_content=426335944&utm_source=hs_email When most people think of vaccines, they think of prevention — an injection that trains the immune system to produce antibodies against infectious diseases such as measles or polio. However, cancer vaccines are different. Rather than preventing disease, cancer vaccines are a type of immunotherapy designed to stimulate the immune system to attack cancer cells that are already present in the body. However, they have historically struggled to deliver consistent clinical benefit.

Colorectal cancer rates are rising in young people. What does that mean for detection and surgical treatment options?

https://www.linkedin.com/pulse/colorectal-cancer-rates-rising-young-people-nucac/ Diagnostic and surgical approaches to treating the disease are evolving—just as rates are spiking. Here’s how the surgical landscape will continue to shift alongside the alarming trend. Back in 2004, Shekar Narayanan, M.D., a colorectal cancer surgeon, treated a 21-year-old woman with early stage colorectal cancer. The patient had a minimally invasive procedure to remove a tumor a few years earlier, but the cancer had returned. Back then, colorectal cancer was considered rare in young adults, so it was common to take a more conservative approach to staging and treatment in this age group. Dr. Narayanan performed a colectomy—an invasive procedure in which a large part of the colon is removed—and created a colostomy, requiring the young patient to use a colostomy bag. Just three years later, at age 24, the cancer had metastasized. By age 25, the patient had died. Treatment for colorectal cancer has come a long way since then. Today, says Dr. Narayanan, that patient would have likely had her lymph nodes removed and examined at the outset instead of relying on a minor surgical procedure. But despite these advances in understanding and treatment, there’s still a long way to go: Colorectal cancer is steadily rising among people in their 20s and 30s, and colorectal cancer surgeons like Dr. Narayanan are screening, testing and treating more young adults than ever before.1 And while diagnostic and treatment approaches continue to advance, the rising rates mean that innovation is crucial to keep pace.  

Global HIV response requires global political support The Lancet HIV +++ +...

Global HIV response requires global political support The Lancet HIV https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00150-5/fulltext?dgcid=raven_jbs_etoc_email Epidemiological and economic effect of preference-driven HIV pre-exposure prophylaxis implementation for men who have sex with men and transgender women across 16 countries and territories in the Asia–Pacific region: a modelling study Shihao He, MPHa ∙ Warittha Tieosapjaroen, PhDb ∙ Xiaoyi Cui, MPHa ∙ Hao Lai, BMa ∙ Ting Zhang, BMa ∙ Yining Bao, MMa ∙ et al. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00053-6/abstract?dgcid=raven_jbs_etoc_feature_lanhiv HIV-1 subtype diversity in Europe Prof Miłosz Parczewski, MD PhDa Send email to milosz.parczewski@pum.edu.pl ∙ Karol Serwin, PhDa ∙ Prof Dimitros Paraskevis, PhDd ∙ Prof Thomas Klimkait, PhDe ∙ Prof Charlotte Charpentier, PharmD PhDf,g ∙ Prof Annemarie Wensing, MD PhD https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00108-6/abstract?dgcid=raven_jbs_etoc_feature_lanhiv Jul 2026 Volume 13Number 7e429-e514 https://www.thelancet.com/journals/lanhiv/issue/vol13no7/PIIS2352-3018(26)X2006-9

A Better Test for Finding Residual Pancreatic Cancer? Megan Brooks +++ +++ +++

A Better Test for Finding Residual Pancreatic Cancer? Megan Brooks https://www.medscape.com/viewarticle/better-test-finding-residual-pancreatic-cancer-2026a1000mjq?src= Clin Cancer Res. 2026; doi:10.1158/1078-0432.CCR-26-0609 AI May Help Predict Liver Cancer Risk in Young Adults Edited by Shrabasti Bhattacharya https://www.medscape.com/viewarticle/ai-may-help-predict-liver-cancer-risk-young-adults-2026a1000mio?src= Aliment Pharmacol Ther. 2026; doi:10.1111/apt.70732 Breast Cancer Incidence Rises in Asian American, Native Hawaiian, and Pacific Islander Women Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/breast-cancer-incidence-rises-asian-american-native-hawaiian-2026a1000mhe?src= JAMA Netw Open. 2026;9(6):e2621250. doi:10.1001/jamanetworkopen.2026.21250 Asian Women With Breast Cancer Outlive White Peers Edited by Katie Lennon https://www.medscape.com/viewarticle/asian-women-breast-cancer-outlive-white-peers-2026a1000mcn?src= Biochem J. 1975;149(3):749-55. doi:10.1042/bj1490749 Q&A: Can More Patients With MIBC Keep Their Bladder? M. Alexander Otto, PA, MMSc https://www.medscape.com/viewarticle/q-can-more-patients-mibc-keep-their-bladder-2026a1000miy?src= July 02, 2026 Urgences 2026 How to Recognize Serious Pediatric Pain Fabienne Rigal https://www.medscape.com/viewarticle/translate-douleurs-p%C3%A9diatriques-aux-urgences-les-2026a1000mi3?src= What ASCO 2026 Taught Us About Scaling AI in Cancer Care Arturo Loaiza-Bonilla, MD, MSEd https://www.medscape.com/viewarticle/what-asco-2026-taught-us-about-scaling-ai-cancer-care-2026a1000l9c?src= FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD M. Alexander Otto, PA, MMSc https://www.medscape.com/viewarticle/fda-approves-orca%E2%80%91t-next%E2%80%91gen-hsct-reduce-2026a1000mg2 July 01, 2026 DISCOVER WHAT YOU CAN ASK MEDSCAPE AI https://www.medscape.com/ai-search?_gl=1*1hc3ubk*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTQ5ODY4MjA4MC4xNzgyOTk5ODc5LjE3ODMwMDAzNTM.

Cancer Disparities Progress Report 2026 Survivors +... +... +...

Cancer Disparities Progress Report 2026 Survivors The goal of cancer research is to save, extend, and enhance the lives of patients with cancer. These cancer survivors have generously shared their stories to highlight how cancer science and medicine is transforming patient care. https://cancerprogressreport.aacr.org/survivor-dis-year/survivors-2026/ Executive Summary This is an extraordinary time in cancer science and medicine. Thanks to decades of research, we are witnessing unprecedented progress against the collection of diseases we call cancer. Yet, these advances have not benefited everyone equally and many segments of the United States (US) population continue to bear a disproportionate burden of cancer. Health care disparities remain among the most profound forms of inequity and injustice, underscoring the urgent need for all stakeholders to eliminate barriers to high-quality health care, the access to which is a fundamental human right. https://cancerprogressreport.aacr.org/disparities/cdpr26-contents/cdpr26-executive-summary/#state https://cancerprogressreport.aacr.org/disparities/